The Europe Diabetes Care Devices Market was valued at USD 14.5 billion in 2024 and is estimated to grow at a CAGR of 12% to reach USD 44.5 billion by 2034.
Alongside this, modern sedentary lifestyles marked by reduced physical activity and poor dietary habits, such as high consumption of processed foods and sugars, are contributing to a growing number of new diabetes diagnoses. As more people live with diabetes, there is a heightened need for reliable, easy-to-use devices that help patients monitor and manage their blood glucose levels effectively.
Major players in the Europe diabetes care devices market are DarioHealth, Medtronic, Ypsomed Holding, F. Hoffmann-La Roche, ARKRAY, Insulet, Sanofi, Dexcom, Nova Biomedical, Novo Nordisk, Ascensia Diabetes Care, Dr. Reddy’s Laboratories, B. Braun Melsungen, Abbott Laboratories, Eli Lilly and Company, Bionime, Becton, Dickinson and Company.
To strengthen their foothold in the Europe diabetes care devices market, companies are implementing strategies that focus on innovation, partnerships, and regional expansion. Leading manufacturers are investing heavily in R&D to create integrated systems combining glucose monitoring, insulin delivery, and AI-driven insights. Strategic collaborations with digital health startups are helping bring data analytics and real-time tracking features into legacy devices.
This product will be delivered within 2-4 business days.
Alongside this, modern sedentary lifestyles marked by reduced physical activity and poor dietary habits, such as high consumption of processed foods and sugars, are contributing to a growing number of new diabetes diagnoses. As more people live with diabetes, there is a heightened need for reliable, easy-to-use devices that help patients monitor and manage their blood glucose levels effectively.
Rising Adoption of Devices
The devices segment held a significant share in 2024, as patients and providers increasingly rely on advanced tools for accurate glucose monitoring and effective insulin delivery. This segment includes a wide range of products such as blood glucose meters, continuous glucose monitors (CGMs), smart insulin pens, and insulin pumps, each playing a vital role in day-to-day disease management. The growing availability of connected devices that integrate with mobile apps and cloud-based systems is transforming how patients track and share their health data.Homecare to Gain Traction
The homecare segment generated robust revenues in 2024, fueled by rising patient preference for self-management and the broader shift toward decentralized healthcare in Europe. With diabetes requiring continuous monitoring and lifestyle adjustments, more patients are seeking solutions that allow for flexible, at-home disease management. The adoption of CGMs, portable insulin pumps, and digital health platforms is making it easier for individuals to monitor their glucose levels without frequent clinical visits.Germany to Emerge as a Propelling Region
Germany diabetes care devices market held a sizeable share in 2024, supported by a robust healthcare system, high public awareness, and widespread access to advanced medical technologies. Germany’s progressive reimbursement policies, particularly for CGMs and insulin pumps, continue to drive demand among both type 1 and type 2 diabetes patients. Additionally, strong physician advocacy for digital tools and early intervention strategies is fueling device adoption.Major players in the Europe diabetes care devices market are DarioHealth, Medtronic, Ypsomed Holding, F. Hoffmann-La Roche, ARKRAY, Insulet, Sanofi, Dexcom, Nova Biomedical, Novo Nordisk, Ascensia Diabetes Care, Dr. Reddy’s Laboratories, B. Braun Melsungen, Abbott Laboratories, Eli Lilly and Company, Bionime, Becton, Dickinson and Company.
To strengthen their foothold in the Europe diabetes care devices market, companies are implementing strategies that focus on innovation, partnerships, and regional expansion. Leading manufacturers are investing heavily in R&D to create integrated systems combining glucose monitoring, insulin delivery, and AI-driven insights. Strategic collaborations with digital health startups are helping bring data analytics and real-time tracking features into legacy devices.
Comprehensive Market Analysis and Forecast
- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter’s Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis
This product will be delivered within 2-4 business days.
Table of Contents
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
Chapter 3 Industry Insights
Chapter 4 Competitive Landscape, 2024
Chapter 5 Market Estimates and Forecast, by Product, 2021-2034 ($ Mn)
Chapter 6 Market Estimates and Forecast, by End Use, 2021-2034 ($ Mn)
Chapter 7 Market Estimates and Forecast, by Country, 2021-2034 ($ Mn)
Chapter 8 Company Profiles
Companies Mentioned
The key companies profiled in this Europe Diabetes Care Devices market report include:- Abbott Laboratories
- ARKRAY
- Ascensia Diabetes Care
- B. Braun Melsungen
- Becton, Dickinson and Company
- Bionime
- DarioHealth
- Dexcom
- Dr. Reddy’s Laboratories
- Eli Lilly and Company
- F. Hoffmann-La Roche
- Insulet
- Medtronic
- Nova Biomedical
- Novo Nordisk
- Sanofi
- Ypsomed Holding
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 110 |
| Published | September 2025 |
| Forecast Period | 2024 - 2034 |
| Estimated Market Value ( USD | $ 14.5 Billion |
| Forecasted Market Value ( USD | $ 44.5 Billion |
| Compound Annual Growth Rate | 12.0% |
| Regions Covered | Europe |
| No. of Companies Mentioned | 18 |
